



INSIDE THIS ISSUE

- Benefit Drug List - Pamidronate
- Protocol Update – BRAVPAM, UGIIRFUFA, GOEP, KSAD, UKSLDO, KSVB, PUM
- Cancer Management Manual
- Pre-Printed Order Update – GIRLAIFF, GIFUR2, UGOCXCAT, GOENDCAT, GOOVCATM, GOOVCATX, GOTDLR, LYCHOP, OSAJAP, OSAVAP
- Drug Update – Exemestane

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BENEFIT DRUG LIST

The indication of pamidronate (Class II drug) has been revised. It is now reimbursed for acute bone pain secondary to metastatic breast cancer in both outpatients and hospital inpatients.

Susan O'Reilly, MB, FRCPC
Provincial Systemic Program Leader

The current Benefit Drug List is available on website <http://bccancer.com>.

PROTOCOL UPDATE

Protocol codes for treatments requiring "Undesignated Indication" approval prior to use are prefixed with the letter **U**.

- **INDEX to BCCA Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **BRAVPAM** revised (eligibility revised) : Treatment of acute bone pain secondary to breast cancer metastases using pamidronate
- **UGIIRFUFA** new protocol: First-line palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)

- **GOEP** revised (typo corrected): Therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide
- **KSAD** reformatted: Palliative therapy for Kaposi's sarcoma using doxorubicin
- **UKSLDO** new: Therapy of Kaposi's sarcoma using liposomal doxorubicin (Caelyx®)
- **KSVB** reformatted: Palliative therapy for Kaposi's sarcoma using vinblastine alternating with vincristine
- **PUM** reformatted: Therapy for metastatic carcinomas of unknown primary using mitomycin

CANCER MANAGEMENT MANUAL

Cancer Management Manual is available on website <http://www.bccancer.bc.ca/cmm>.

PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BCCA protocol summaries. The Vancouver Cancer Centre has prepared the following chemotherapy pre-printed orders, which can be used as a guide for reference:

- **GIRLAIFF** new: Pre-operative concurrent chemotherapy and radiotherapy and post operative chemotherapy for locally advanced (borderline resectable or unresectable) rectal adenocarcinoma
- **GIFUR2** revised: Combined modality adjuvant therapy for high risk rectal carcinoma using fluorouracil, leucovorin, and radiation therapy
- **UGOCXCAT** new (pre-printed order titled GOCAT): Primary treatment of advanced/recurrent non-small cell cancer of the cervix.
- **GOENDCAT** revised (pre-printed order titled GOCAT): Treatment of primarily advanced or recurrent endometrial cancer using carboplatin and paclitaxel
- **GOOVCATM** revised (pre-printed order titled GOCAT): Primary treatment of invasive

epithelial ovarian, fallopian tube and primary peritoneal cancer, with no visible residual tumour (moderate-high risk) using Paclitaxel and Carboplatin

- GOOVCATX revised (pre-printed order titled GOCAT): Primary treatment of visible residual (extreme risk) invasive epithelial ovarian cancer in ambulatory care settings using paclitaxel and carboplatin
- GOTDLR new: Therapy for low risk gestational trophoblastic neoplasia using methotrexate, leucovorin and actinomycin D
- LYCHOP new: Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP)
- OSAJAP revised (pre-printed order titled OSAJAP-VAP): Adjuvant therapy for osteosarcoma using doxorubicin (Adriamycin®) and cisplatin
- OSAVAP revised (pre-printed order titled OSAJAP-VAP): Therapy of advanced osteosarcoma using doxorubicin (Adriamycin®) and cisplatin

An index to the orders can be obtained by Fax-back.

DRUG UPDATE

Exemestane (Aromasin®) is a new oral aromatase inhibitor which has been recently released in Canada for the treatment of advanced breast cancer in postmenopausal women. The BCCA Breast Tumour Group is currently reviewing the role of exemestane in the hormonal treatment of breast cancer. Exemestane is not currently on the BCCA Benefit Drug List.

Editorial Review Board

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD
 Sandi Broughton, BA(Econ), MSc
 Jack Chritchley, MD
 Linda Yearwood, MSN
 Lynne Nakashima, PharmD
 David Noble, BSc, BLS
 Lynn Stevenson, RN
 Kelly Uyeno, CGA

Gigi Concon (Secretary)

IN TOUCH	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Communities Oncology Network	Ext 2744	bfiddler@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 2515	mfung@bccancer.bc.ca
Drug Information	Ext 3028	robrien@bccancer.bc.ca
Library / Cancer Information	Ext 2690	dnoble@bccancer.bc.ca
Update Editor	Ext 2288	mdelemos@bccancer.bc.ca
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 370-8228	Toll-Free 1-(800)-670-3322

BCCA SYSTEMIC THERAPY UPDATE**FAX REQUEST FORM**

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247**OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247****PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES***I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:* E-mail (Word 6.0) Fax

	@	
()		Attn:

UPDATES Please Fax-Back information below:

<input type="checkbox"/> All items
Patient Handouts:
<input type="checkbox"/> <input type="checkbox"/>
<input type="checkbox"/> <input type="checkbox"/>
<input type="checkbox"/> <input type="checkbox"/>
Pre-Printed Orders:
<input type="checkbox"/> GIRLAIFF <input type="checkbox"/> GIFUR2
<input type="checkbox"/> UGOCXCAT <input type="checkbox"/> GOENCAT
<input type="checkbox"/> GOOVCATM <input type="checkbox"/> GOOVCATX
<input type="checkbox"/> GOTDLR <input type="checkbox"/> LYCHOP
<input type="checkbox"/> OSAJAP <input type="checkbox"/> OSAVAP
<input type="checkbox"/> Index: Pre-Printed Orders
Protocol Summaries:
<input type="checkbox"/> BRAVPAM <input type="checkbox"/> UGIIRFUFA
<input type="checkbox"/> GOEP <input type="checkbox"/> KSAD
<input type="checkbox"/> UKSLDO <input type="checkbox"/> KSVB
<input type="checkbox"/> PUM <input type="checkbox"/>
<input type="checkbox"/> Index: Protocol Summaries (current month)
Reimbursement
<input type="checkbox"/> Benefit Drug List (01 October 2000)
<input type="checkbox"/> Class 2 Form (01 October 2000)
Systemic Therapy Update Index
<input type="checkbox"/> Jan-July 2000

REGIONAL CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION
Patient Handouts:	H:\everyone\systemic\chemo\Pt_Educ
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\VCC
Index of Pre-Printed Orders	Index.doc
	GIRLAIFF
	GIFUR2
	GOCAT
	GOTDLR
	LYCHOP
	OSAJAP-VAP
Protocol Summaries	H:\everyone\systemic\chemo\Protocol*tumour site*
	BRAVPAM
	UGIRFUFA
	GOEP
	KSAD
	UKSLDO
	KSVB
	PUM
Index of Protocol Summaries	Index_NT or Index_W6
Reimbursement	H:\everyone\systemic\chemo\Reimburs
Benefit Drug List (01 October 2000)	BenefitList.doc
Class 2 Form (01 October 2000)	Class2.doc

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca